Cargando…

Validation of a novel point of care testing device for sickle cell disease

BACKGROUND: Sickle cell disease is one of the most common inherited blood disorders. Universal screening and early intervention have significantly helped to reduce childhood mortality in high-resource countries. However, persons living in low-resource settings are often not diagnosed until late chil...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanter, Julie, Telen, Marilyn J., Hoppe, Carolyn, Roberts, Christopher L., Kim, Jason S., Yang, Xiaoxi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573998/
https://www.ncbi.nlm.nih.gov/pubmed/26377572
http://dx.doi.org/10.1186/s12916-015-0473-6
_version_ 1782390546582470656
author Kanter, Julie
Telen, Marilyn J.
Hoppe, Carolyn
Roberts, Christopher L.
Kim, Jason S.
Yang, Xiaoxi
author_facet Kanter, Julie
Telen, Marilyn J.
Hoppe, Carolyn
Roberts, Christopher L.
Kim, Jason S.
Yang, Xiaoxi
author_sort Kanter, Julie
collection PubMed
description BACKGROUND: Sickle cell disease is one of the most common inherited blood disorders. Universal screening and early intervention have significantly helped to reduce childhood mortality in high-resource countries. However, persons living in low-resource settings are often not diagnosed until late childhood when they present with clinical symptoms. In addition, confirmation of disease in affected individuals in the urgent care setting is limited in both high- and low-resource areas, often leading to delay in treatment. All of the current diagnostic methods rely on advanced laboratory systems and are often prohibitively expensive and time-consuming in low-resource settings. To address this need, the Sickle SCAN™ test has been developed to diagnose sickle cell disease and sickle cell trait at the point of care without electricity or advanced equipment. METHODS: This study was conducted to evaluate and validate the diagnostic accuracy of the Sickle SCAN™ test, a novel point of care test for sickle cell disease. Thus, we describe the laboratory testing and clinical validation of the Sickle SCAN™ test in individuals >1 year of age using capillary blood. The Sickle SCAN™ test was created using advanced, qualitative lateral flow technology using capillary blood to identify the presence of hemoglobin A, S, and C allowing for detection of results with the naked eye. RESULTS: Laboratory testing using venous blood demonstrated 99 % sensitivity and 99 % specificity for the diagnosis of HbSS, HbAS, HbSC, HbAC, and HbAA. Seventy-one subjects underwent capillary blood sampling at the point of care for further validation. This test detected the correct A, S, and C presence with an overall diagnostic accuracy of 99 % at the bedside. CONCLUSION: The Sickle SCAN™ test has the potential to significantly impact the diagnosis and treatment for sickle cell disease worldwide as well as enhance genetic counseling at the point of care. Further validation testing will be conducted in newborns in resource-poor settings in upcoming studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12916-015-0473-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4573998
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45739982015-09-19 Validation of a novel point of care testing device for sickle cell disease Kanter, Julie Telen, Marilyn J. Hoppe, Carolyn Roberts, Christopher L. Kim, Jason S. Yang, Xiaoxi BMC Med Technical Advance BACKGROUND: Sickle cell disease is one of the most common inherited blood disorders. Universal screening and early intervention have significantly helped to reduce childhood mortality in high-resource countries. However, persons living in low-resource settings are often not diagnosed until late childhood when they present with clinical symptoms. In addition, confirmation of disease in affected individuals in the urgent care setting is limited in both high- and low-resource areas, often leading to delay in treatment. All of the current diagnostic methods rely on advanced laboratory systems and are often prohibitively expensive and time-consuming in low-resource settings. To address this need, the Sickle SCAN™ test has been developed to diagnose sickle cell disease and sickle cell trait at the point of care without electricity or advanced equipment. METHODS: This study was conducted to evaluate and validate the diagnostic accuracy of the Sickle SCAN™ test, a novel point of care test for sickle cell disease. Thus, we describe the laboratory testing and clinical validation of the Sickle SCAN™ test in individuals >1 year of age using capillary blood. The Sickle SCAN™ test was created using advanced, qualitative lateral flow technology using capillary blood to identify the presence of hemoglobin A, S, and C allowing for detection of results with the naked eye. RESULTS: Laboratory testing using venous blood demonstrated 99 % sensitivity and 99 % specificity for the diagnosis of HbSS, HbAS, HbSC, HbAC, and HbAA. Seventy-one subjects underwent capillary blood sampling at the point of care for further validation. This test detected the correct A, S, and C presence with an overall diagnostic accuracy of 99 % at the bedside. CONCLUSION: The Sickle SCAN™ test has the potential to significantly impact the diagnosis and treatment for sickle cell disease worldwide as well as enhance genetic counseling at the point of care. Further validation testing will be conducted in newborns in resource-poor settings in upcoming studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12916-015-0473-6) contains supplementary material, which is available to authorized users. BioMed Central 2015-09-16 /pmc/articles/PMC4573998/ /pubmed/26377572 http://dx.doi.org/10.1186/s12916-015-0473-6 Text en © Kanter et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Technical Advance
Kanter, Julie
Telen, Marilyn J.
Hoppe, Carolyn
Roberts, Christopher L.
Kim, Jason S.
Yang, Xiaoxi
Validation of a novel point of care testing device for sickle cell disease
title Validation of a novel point of care testing device for sickle cell disease
title_full Validation of a novel point of care testing device for sickle cell disease
title_fullStr Validation of a novel point of care testing device for sickle cell disease
title_full_unstemmed Validation of a novel point of care testing device for sickle cell disease
title_short Validation of a novel point of care testing device for sickle cell disease
title_sort validation of a novel point of care testing device for sickle cell disease
topic Technical Advance
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573998/
https://www.ncbi.nlm.nih.gov/pubmed/26377572
http://dx.doi.org/10.1186/s12916-015-0473-6
work_keys_str_mv AT kanterjulie validationofanovelpointofcaretestingdeviceforsicklecelldisease
AT telenmarilynj validationofanovelpointofcaretestingdeviceforsicklecelldisease
AT hoppecarolyn validationofanovelpointofcaretestingdeviceforsicklecelldisease
AT robertschristopherl validationofanovelpointofcaretestingdeviceforsicklecelldisease
AT kimjasons validationofanovelpointofcaretestingdeviceforsicklecelldisease
AT yangxiaoxi validationofanovelpointofcaretestingdeviceforsicklecelldisease